Glomerulonephritis membranous – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:22:13 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Glomerulonephritis membranous – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Povetacicept Compared to Tacrolimus for Adults with Primary Membranous Nephropathy https://clinicaltrials.eu/trial/a-study-of-povetacicept-compared-to-tacrolimus-for-adults-with-primary-membranous-nephropathy/ Wed, 29 Apr 2026 15:08:07 +0000 https://clinicaltrials.eu/trial/a-study-of-povetacicept-compared-to-tacrolimus-for-adults-with-primary-membranous-nephropathy/ This study involves people with Primary Membranous Nephropathy, a kidney disease where the filtering units of the kidneys become damaged and thickened, leading to protein leaking into the urine. The study will test a treatment called ALPN-303, which is also known as povetacicept, and compare it to a standard treatment called a calcineurin inhibitor, which in this study is tacrolimus. Povetacicept is given as an injection under the skin, while tacrolimus is taken by mouth as a capsule. The purpose of the study is to find out how well povetacicept works in treating this kidney condition and to check how safe it is.

Participants will be randomly assigned to receive either povetacicept or tacrolimus. The study will last up to 72 weeks, during which time participants will receive their assigned treatment and attend regular visits for monitoring. During these visits, various tests will be performed to check kidney function, measure protein levels in the urine, and monitor overall health. Blood tests, heart tracings, and other measurements will be taken to ensure the treatments are working properly and to watch for any unwanted effects.

The main goal is to see how many participants achieve complete remission of their kidney disease, which means their kidney function has improved and the amount of protein in their urine has decreased to normal or near-normal levels. The study will also look at different definitions of improvement and will carefully track any side effects or health changes that occur during treatment. This information will help doctors understand whether povetacicept could be a useful treatment option for people with this type of kidney disease.

]]> Study of obinutuzumab to reduce PLA2R antibodies in patients with primary membranous nephropathy https://clinicaltrials.eu/trial/study-of-obinutuzumab-to-reduce-pla2r-antibodies-in-patients-with-primary-membranous-nephropathy/ Wed, 29 Apr 2026 15:06:51 +0000 https://clinicaltrials.eu/trial/study-of-obinutuzumab-to-reduce-pla2r-antibodies-in-patients-with-primary-membranous-nephropathy/ This clinical trial focuses on patients with primary membranous nephropathy, a kidney disease where the body’s immune system attacks the filtering membranes in the kidneys, causing protein loss in urine. The study investigates the use of obinutuzumab (also known as Gazyvaro), a medication that is given through an intravenous infusion. This medicine belongs to a group of drugs that target specific proteins in the immune system.

The purpose of the study is to understand how quickly certain antibodies (called PLA2R antibodies) disappear from the blood after treatment with obinutuzumab. Patients will receive a total of 4000 mg of the medication, administered as 1000 mg doses. The treatment period lasts for approximately 12 months, during which regular blood tests will be performed to measure antibody levels.

Throughout the study, doctors will monitor how well the treatment works by checking protein levels in urine and blood. They will also track the patients’ overall health and quality of life. The medication will be given in a healthcare setting where medical professionals can monitor for any side effects during and after the infusion.

]]> Study of Atacicept Treatment for Patients with Multiple Autoimmune Glomerular Diseases https://clinicaltrials.eu/trial/study-of-atacicept-treatment-for-patients-with-multiple-autoimmune-glomerular-diseases/ Wed, 29 Apr 2026 15:06:35 +0000 https://clinicaltrials.eu/trial/study-of-atacicept-treatment-for-patients-with-multiple-autoimmune-glomerular-diseases/ This clinical trial focuses on testing a medication called atacicept (VT-001) in people with Multiple Autoimmune Glomerular Diseases. These are conditions where the immune system attacks the kidneys’ filtering units, leading to protein leakage into urine. The study specifically looks at different types of kidney diseases, including IgA Nephropathy, Membranous Nephropathy, Minimal Change Disease, and Focal Segmental Glomerulosclerosis.

The purpose of this study is to evaluate how safe atacicept is and how well it works in reducing the amount of protein in the urine. The medication is given as a subcutaneous injection using a pre-filled syringe. Participants will receive treatment while continuing their regular standard of care medications as prescribed by their doctors.

The study will last for 52 weeks, during which participants will receive regular doses of atacicept. Throughout the study, doctors will monitor various aspects of kidney function, particularly the amount of protein in the urine and how well the kidneys are filtering blood. They will also track the levels of specific disease markers in the blood that are associated with each type of kidney disease.

]]> Evaluating Dapagliflozin’s Effect on Immune Activity in Patients with Membranous Nephropathy https://clinicaltrials.eu/trial/evaluating-dapagliflozins-effect-on-immune-activity-in-patients-with-membranous-nephropathy/ Wed, 29 Apr 2026 15:06:07 +0000 https://clinicaltrials.eu/trial/evaluating-dapagliflozins-effect-on-immune-activity-in-patients-with-membranous-nephropathy/ This clinical trial investigates the effects of dapagliflozin on Membranous Nephropathy, a kidney disease where the body’s immune system attacks the kidney’s filtering system. Membranous Nephropathy is associated with anti-PLA2R1 autoantibodies, which are proteins produced by the immune system that mistakenly target structures in the kidney. The purpose of the study is to evaluate how dapagliflozin affects these autoantibody levels in patients experiencing an immunological relapse of the disease.

The study will monitor patients over a 6-month period while they receive dapagliflozin treatment. During this time, researchers will track changes in antibody levels, protein in urine (proteinuria), albumin (a protein in blood), and kidney function as measured by glomerular filtration rate (how well the kidneys filter waste). The study will also analyze changes in various immune system signaling molecules called cytokines to better understand how the medication affects the immune response.

Participants will continue their existing antiproteinuric treatment (medication that reduces protein in urine) while adding dapagliflozin to their regimen. The safety and tolerance of dapagliflozin will be closely monitored throughout the study period to ensure participant wellbeing.

]]> Study on the Effectiveness and Safety of Obinutuzumab and Tacrolimus for Patients with Primary Membranous Nephropathy https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-obinutuzumab-and-tacrolimus-for-patients-with-primary-membranous-nephropathy/ Wed, 29 Apr 2026 14:48:01 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-obinutuzumab-and-tacrolimus-for-patients-with-primary-membranous-nephropathy/ This clinical trial is focused on studying a kidney condition known as Primary Membranous Nephropathy (pMN). The study is evaluating the effectiveness and safety of a medication called Obinutuzumab, which is compared to another treatment known as Tacrolimus. Obinutuzumab is given as an infusion, which means it is administered directly into the bloodstream through a vein, while Tacrolimus is taken orally in the form of capsules.

The purpose of the study is to determine how well Obinutuzumab works compared to Tacrolimus in helping patients achieve a complete remission, which means the symptoms of the disease are significantly reduced or disappear. The study will last for a period of 104 weeks, during which participants will receive either Obinutuzumab or Tacrolimus. Throughout the study, participants will be monitored to see how their condition responds to the treatment and to check for any side effects.

Participants will be assessed at various points during the study to see if they achieve remission and to monitor their overall health. The study aims to provide valuable information on the potential benefits and risks of using Obinutuzumab for treating Primary Membranous Nephropathy, which could help improve treatment options for patients with this condition in the future.

]]> Study of Felzartamab for Patients with Membranous Nephropathy Resistant to Anti-CD20 Therapy https://clinicaltrials.eu/trial/study-of-felzartamab-for-patients-with-membranous-nephropathy-resistant-to-anti-cd20-therapy/ Wed, 29 Apr 2026 14:28:06 +0000 https://clinicaltrials.eu/trial/study-of-felzartamab-for-patients-with-membranous-nephropathy-resistant-to-anti-cd20-therapy/ This clinical trial is focused on studying a condition called membranous nephropathy, which affects the kidneys and can lead to a condition known as nephrotic syndrome. Nephrotic syndrome is characterized by high levels of protein in the urine, which can cause swelling and other health issues. The study is testing a treatment called Felzartamab, also known by its code name MOR202. Felzartamab is a type of medication known as a monoclonal antibody, which is designed to target specific proteins in the body. The purpose of the study is to see if Felzartamab can help reduce the amount of protein in the urine of patients who have not responded well to previous treatments.

Participants in the study will receive Felzartamab through an infusion, which means the medication is given directly into the bloodstream. The study will last for up to 24 months, during which time participants will have regular check-ups to monitor their health and the effects of the treatment. The study will also involve the use of other medications, such as Aminohippuric Acid and Omnipaque, which are used for diagnostic purposes to help doctors better understand how the kidneys are functioning.

The main goal of the study is to determine if Felzartamab can effectively reduce the protein levels in the urine of patients with membranous nephropathy. Researchers will also look at other health indicators, such as kidney function and overall quality of life, to assess the impact of the treatment. The study will help provide valuable information about the potential benefits and risks of using Felzartamab for this condition.

]]> Study of Zanubrutinib and Tacrolimus for Patients with Primary Membranous Nephropathy https://clinicaltrials.eu/trial/study-of-zanubrutinib-and-tacrolimus-for-patients-with-primary-membranous-nephropathy/ Wed, 29 Apr 2026 14:27:01 +0000 https://clinicaltrials.eu/trial/study-of-zanubrutinib-and-tacrolimus-for-patients-with-primary-membranous-nephropathy/ This clinical trial is focused on studying a kidney condition called Primary Membranous Nephropathy. This condition affects the filtering units of the kidneys, leading to protein loss in the urine. The study will compare the effectiveness and safety of two medications: Zanubrutinib and Tacrolimus. Zanubrutinib, also known by its code name BGB-3111, is a medication that may help reduce protein loss in the urine. Tacrolimus is another medication that is commonly used to suppress the immune system and is being used as a comparison in this study.

The purpose of the study is to evaluate how well Zanubrutinib works in reducing protein in the urine and achieving complete remission, which means the disease is no longer active. The study will be conducted in two parts. In the first part, participants will receive Zanubrutinib to see how it affects protein levels in the urine. In the second part, participants will be randomly assigned to receive either Zanubrutinib or Tacrolimus to compare their effectiveness in achieving complete remission.

Participants will take the medications in capsule form by mouth. The study will last for a period of up to 64 weeks, during which time participants will have regular check-ups to monitor their health and the effects of the medication. The study aims to provide valuable information on the potential benefits of Zanubrutinib for people with Primary Membranous Nephropathy.

]]> Study of Peginterferon Alfa-2a for Patients with Extramembranous Glomerulonephritis https://clinicaltrials.eu/trial/study-of-peginterferon-alfa-2a-for-patients-with-extramembranous-glomerulonephritis/ Wed, 29 Apr 2026 14:24:12 +0000 https://clinicaltrials.eu/trial/study-of-peginterferon-alfa-2a-for-patients-with-extramembranous-glomerulonephritis/ This clinical trial is focused on studying the effects of a treatment for a kidney condition known as extramembranous glomerulonephritis. This condition involves inflammation of the tiny filters in the kidneys, which can lead to kidney damage. The treatment being tested is called Pegasys, which is a form of medication known as peginterferon alfa-2a. It is administered as a solution for injection using a pre-filled syringe.

The purpose of the study is to observe the immune system’s activity in patients with this kidney condition who have experienced a return of symptoms. The study will involve a personalized approach to therapy, focusing on a specific part of the immune system known as the Th17 pathway. Patients will receive the Pegasys treatment over a period of six months. During this time, researchers will monitor changes in certain antibodies and proteins in the blood, which are indicators of the body’s immune response.

Participants in the study will receive regular injections of Pegasys and will have their blood tested to measure levels of specific antibodies and proteins. The study aims to determine how the treatment affects these levels and to assess the overall tolerance of the therapy. The goal is to find an effective treatment regimen that can help manage the condition by reducing certain immune system markers.

]]> Study of Obinutuzumab for Patients with Primary Membranous Nephropathy Resistant or Intolerant to Rituximab https://clinicaltrials.eu/trial/study-of-obinutuzumab-for-patients-with-primary-membranous-nephropathy-resistant-or-intolerant-to-rituximab/ Wed, 29 Apr 2026 14:23:02 +0000 https://clinicaltrials.eu/trial/study-of-obinutuzumab-for-patients-with-primary-membranous-nephropathy-resistant-or-intolerant-to-rituximab/ This clinical trial is focused on studying a kidney condition known as Primary Membranous Nephropathy. This condition can lead to a group of symptoms called nephrotic syndrome, which includes high levels of protein in the urine, low levels of protein in the blood, and swelling. The study is testing a medication called Obinutuzumab to see if it can help patients who have not responded well to another treatment called rituximab. Some patients may be resistant to rituximab, meaning it doesn’t work for them, or they may be dependent on it, meaning they need it regularly to manage their symptoms. Others may be intolerant, meaning they cannot take rituximab due to severe side effects.

The purpose of the study is to evaluate if Obinutuzumab can help these patients achieve remission, which means reducing or eliminating the symptoms of nephrotic syndrome. The study will also assess if the medication is safe and well-tolerated. Participants will receive the treatment and be monitored over a period of time to see how their condition changes. The study will look at how many patients experience a complete or partial remission of their symptoms and will also track any side effects that occur during the treatment.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. This includes measuring protein levels in the urine and blood, as well as other health indicators. The study aims to provide valuable information on the effectiveness and safety of Obinutuzumab for patients with Primary Membranous Nephropathy who have limited treatment options due to their response to rituximab.

]]> Study on the Safety and Effects of AP1189 for Patients with Idiopathic Membranous Nephropathy and Severe Proteinuria https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-ap1189-for-patients-with-idiopathic-membranous-nephropathy-and-severe-proteinuria/ Wed, 29 Apr 2026 14:22:38 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-ap1189-for-patients-with-idiopathic-membranous-nephropathy-and-severe-proteinuria/ This clinical trial is focused on studying a kidney condition known as idiopathic membranous nephropathy, which is characterized by severe protein loss in the urine, a condition called severe proteinuria. The trial is testing a new treatment called the AP1189 Tablet, which contains the active substance resomelagon. This treatment is being compared to a placebo to see how safe and effective it is when used alongside standard treatments like ACE inhibitors or angiotensin II receptor blockers, which are commonly used to manage blood pressure and kidney function.

The purpose of the study is to evaluate the safety and effectiveness of the AP1189 Tablet over a period of 12 weeks. Participants will receive either the AP1189 Tablet or a placebo daily. Throughout the study, researchers will monitor participants’ health by checking for any side effects, changes in vital signs, and conducting tests like electrocardiograms and laboratory assessments. The main focus will be on how the treatment affects the amount of protein lost in urine over the 12-week period.

Participants will be closely observed to see if there are any improvements in their condition, such as a reduction in protein loss or improvements in kidney function. The study will also look at changes in other health markers, like albumin levels in the blood and kidney filtration rates. The goal is to determine if the AP1189 Tablet can help manage the symptoms of idiopathic membranous nephropathy more effectively than current treatments alone.

]]>